CFTR and cystic fibrosis: To date, TEZ and ELX demonstrated the best pharmacological properties and clinical efficacy in rescuing p.Phe508del CFTR. ELX in particular allowed to target new CF subpopulations including those carrying p.Phe508del and either residual or minimal function mutations.